Clinical Trials Logo

Opioid Use Disorder, Severe clinical trials

View clinical trials related to Opioid Use Disorder, Severe.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04921787 Recruiting - Clinical trials for Substance Use Disorders

EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy

EXHITENTRE
Start date: October 22, 2021
Phase: N/A
Study type: Interventional

This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented.

NCT ID: NCT04850664 Recruiting - Craving Clinical Trials

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

CBOT-OUD
Start date: March 26, 2021
Phase: Phase 2
Study type: Interventional

Opioid Use Disorders (OUD) cause significant burden to individuals, families, and the society. Our product - Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) - offers a cost-saving, home-based, user-friendly brain stimulation system that increased 6-month treatment retention of OUDs in a pilot study; and also, acutely reduced opioid withdrawal severity and negative affect during induction into opioid maintenance therapy. This study will establish its effectiveness in a broad category of OUD subjects at different stages of OUD care continuum.

NCT ID: NCT04345718 Recruiting - Clinical trials for Substance Use Disorder

EXHIT ENTRE Comparative Effectiveness Trial

EXHITENTRE
Start date: August 9, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an addiction consultation service (ACS) and agreeing to initiate a medication for OUD (MOUD). Participants will be randomly assigned to XR-BUP or TAU to be received within 72 hours of anticipated hospital discharge. Follow up will occur at approximately 34, 90, and 180 days following hospital discharge.